Point72 Europe London LLP Takes Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Point72 Europe London LLP purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 6,983 shares of the biotechnology company’s stock, valued at approximately $872,000.

Other institutional investors also recently modified their holdings of the company. Fifth Third Wealth Advisors LLC bought a new position in Sarepta Therapeutics in the second quarter worth approximately $607,000. Teachers Retirement System of The State of Kentucky bought a new position in Sarepta Therapeutics in the second quarter worth approximately $4,771,000. Simplify Asset Management Inc. boosted its holdings in Sarepta Therapeutics by 84.6% in the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock worth $24,105,000 after acquiring an additional 88,474 shares in the last quarter. Securian Asset Management Inc. bought a new position in Sarepta Therapeutics in the second quarter worth approximately $1,187,000. Finally, Natixis Advisors LLC bought a new position in Sarepta Therapeutics in the second quarter worth approximately $1,918,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on SRPT shares. HC Wainwright began coverage on Sarepta Therapeutics in a report on Monday, November 25th. They issued a “sell” rating and a $80.00 price target on the stock. Guggenheim increased their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Finally, Jefferies Financial Group began coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average target price of $175.77.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $133.34 on Friday. The stock has a market cap of $12.74 billion, a PE ratio of 106.67 and a beta of 0.81. Sarepta Therapeutics, Inc. has a fifty-two week low of $78.67 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock has a fifty day moving average of $122.50 and a 200-day moving average of $131.49.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.